Genetic analysis of dasatinib-treated chronic myeloid leukemia rapidly developing into acute myeloid leukemia with monosomy 7 in Philadelphia-negative cells

Myelodysplastic Syndrome with Ph Negative Monosomy 7 Chromosome following Transient Bone Marrow Dysplasia during Imatinib Treatment for Chronic Myeloid Leukemia

“…Taken together, the inhibition of signal transduction in molecules other than BCR-ABL in normal hematopoietic stem cells may cause MDS during imatinib treatment. Chromosomal abnormality has also been reported in patients treated with nilotinib or dasatinib (22)(23)(24). Fur- ther study is needed to elucidate the cause of chromosomal abnormality during treatment with tyrosine kinase inhibitors.…”

Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report

“…Most abnormalities are similar to those associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), including trisomy 8, monosomy 7 and 20q-. Based on published data, CML patients that develop chromosome 7 abnormalities in PhÀ cells, particularly monosomy 7, appear to have the greatest risk of developing MDS/AML [6,12,13]. We report a case of a CML patient who achieved complete hematologic, cytogenetic, and molecular remission on nilotinib as a first-line treatment, but was found to develop monosomy 7 in PhÀ cells.…”

“…Tyrosine kinase inhibitors (TKIs) block the initiation of the BCR‐ABL1 pathway, and are currently used as a first‐line treatment for CML patients. However, it has been reported that after treatment with TKIs, Philadelphia chromosome negative (Ph‐negative) clones can emerge with various cytogenetic abnormalities associated with different outcomes . Most abnormalities are similar to those associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), including trisomy 8, monosomy 7 and 20q‐.…”

Myelodysplastic syndrome (MDS)-associated cytogenetic abnormalities in pediatric chronic myelogenous leukemia

“…Some studies have shown the occurrence of cytogenetic abnormalities such as monosomy 7, deletion 20q, and trisomy 8 in Ph− clones following treatment with first and second generation TKIs . Some of these changes were associated with the development of overt myelodysplastic syndrome (MDS), whereas others were transient without clinical implications .…”